Core Viewpoint - In the first ten months of the year, Gansu Province's total import and export value with other RCEP member countries exceeded 15 billion yuan, marking a year-on-year increase of 43.2% [1] Group 1: Trade Performance - Gansu's import and export value with RCEP countries reached 15.75 billion yuan, reflecting a significant growth of 43.2% compared to the previous year [1] - The RCEP agreement, being the largest free trade agreement in terms of population and economic scale, serves as a crucial bridge for Gansu to connect with the Asia-Pacific market [1] Group 2: Policy and Support Measures - Over the past five years, Lanzhou Customs has established a comprehensive policy service system aimed at key industries such as agricultural products, traditional Chinese medicine, and new materials [1] - The implementation of the "Customs Director delivers policies to the door" mechanism has allowed for precise alignment with enterprise needs [1] - Customs has enhanced the convenience of issuing certificates of origin, adopting an "online review + self-service printing" model, which significantly reduces customs clearance time and lowers trade costs [1]

《2024年度环境、社会和公司治理(ESG)报告》封面 中国医药秉持"人才为本，质量为核"的核心理念，积极履行人文关怀，帮扶困难员工。公司不断完善质量管理体系，强化全员质量意识，中国医药及下属单 位中21家公司通过29项ISO9001、ISO13485质量管理体系认证，以严苛标准铸就品质标杆，持续以优质服务提升客户满意度。在供应链管理层面，中国医药 依托"客商云"及商贸ERP系统，搭建供应商管理数字化平台，以数字技术赋能管理升级，持续完善供应商管理与沟通机制，推动供应链绿色转型，携手供应 商共建阳光、诚信、可持续的供应生态。此外，中国医药投身公益事业，助力乡村振兴，立足专业优势，优选中药材产品，整合地方特色食品、农副产品以 在全球可持续发展浪潮下，中国医药（600056）健康产业股份有限公司(600056.SH)(以下简称"中国医药")始终秉持"责任治理"与"责任发展"理念，将环境、 社会和公司治理(ESG)融入战略核心。2025年4月26日，公司发布《2024年度环境、社会和公司治理(ESG)报告》(以下简称"本报告")，系统披露了其在绿色 转型、社会责任、治理创新等方面的实践与成效。中国医药立足"科、工、 ...